These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38924406)

  • 1. The annotation of
    Gustavsson EK; Sethi S; Gao Y; Brenton JW; García-Ruiz S; Zhang D; Garza R; Reynolds RH; Evans JR; Chen Z; Grant-Peters M; Macpherson H; Montgomery K; Dore R; Wernick AI; Arber C; Wray S; Gandhi S; Esselborn J; Blauwendraat C; Douse CH; Adami A; Atacho DAM; Kouli A; Quaegebeur A; Barker RA; Englund E; Platt F; Jakobsson J; Wood NW; Houlden H; Saini H; Bento CF; Hardy J; Ryten M
    Sci Adv; 2024 Jun; 10(26):eadk1296. PubMed ID: 38924406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p.
    Straniero L; Rimoldi V; Samarani M; Goldwurm S; Di Fonzo A; Krüger R; Deleidi M; Aureli M; Soldà G; Duga S; Asselta R
    Sci Rep; 2017 Oct; 7(1):12702. PubMed ID: 28983119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex distribution and classification of GBA1 variants in an Italian cohort of Parkinson's disease patients analyzed over the last seventeen years.
    Panteghini C; Reale C; Colangelo I; Suerz M; Catania A; Garavaglia B; Invernizzi F
    Parkinsonism Relat Disord; 2023 Dec; 117():105919. PubMed ID: 37948831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic variation in the CpG island of pseudogene GBAP1 promoter is associated with gastric cancer susceptibility.
    Ma G; Liu H; Du M; Zhang G; Lin Y; Ge Y; Wang M; Jin G; Zhao Q; Chu H; Gong W; Zhang Z
    Cancer; 2019 Jul; 125(14):2465-2473. PubMed ID: 30951202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
    Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
    Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation.
    Sheth J; Bhavsar R; Mistri M; Pancholi D; Bavdekar A; Dalal A; Ranganath P; Girisha KM; Shukla A; Phadke S; Puri R; Panigrahi I; Kaur A; Muranjan M; Goyal M; Ramadevi R; Shah R; Nampoothiri S; Danda S; Datar C; Kapoor S; Bhatwadekar S; Sheth F
    BMC Med Genet; 2019 Feb; 20(1):31. PubMed ID: 30764785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects,
    Zhao X; Lin Y; Liou B; Fu W; Jian J; Fannie V; Zhang W; Setchell KDR; Grabowski GA; Sun Y; Liu CJ
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2210442120. PubMed ID: 36574647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations.
    Abeliovich A; Hefti F; Sevigny J
    J Parkinsons Dis; 2021; 11(s2):S183-S188. PubMed ID: 34151863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
    Farfel-Becker T; Do J; Tayebi N; Sidransky E
    Trends Neurosci; 2019 Sep; 42(9):631-643. PubMed ID: 31288942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase and its relevance to Parkinson disease.
    Do J; McKinney C; Sharma P; Sidransky E
    Mol Neurodegener; 2019 Aug; 14(1):36. PubMed ID: 31464647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease.
    Yildiz Y; Hoffmann P; Vom Dahl S; Breiden B; Sandhoff R; Niederau C; Horwitz M; Karlsson S; Filocamo M; Elstein D; Beck M; Sandhoff K; Mengel E; Gonzalez MC; Nöthen MM; Sidransky E; Zimran A; Mattheisen M
    Orphanet J Rare Dis; 2013 Sep; 8():151. PubMed ID: 24070122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.
    Burke DG; Rahim AA; Waddington SN; Karlsson S; Enquist I; Bhatia K; Mehta A; Vellodi A; Heales S
    J Inherit Metab Dis; 2013 Sep; 36(5):869-72. PubMed ID: 23151684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
    Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
    Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson's disease-associated GBA gene.
    Toffoli M; Chen X; Sedlazeck FJ; Lee CY; Mullin S; Higgins A; Koletsi S; Garcia-Segura ME; Sammler E; Scholz SW; Schapira AHV; Eberle MA; Proukakis C
    Commun Biol; 2022 Jul; 5(1):670. PubMed ID: 35794204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson's study.
    Pachchek S; Landoulsi Z; Pavelka L; Schulte C; Buena-Atienza E; Gross C; Hauser AK; Reddy Bobbili D; Casadei N; May P; Krüger R;
    NPJ Parkinsons Dis; 2023 Nov; 9(1):156. PubMed ID: 37996455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.
    Duran R; Mencacci NE; Angeli AV; Shoai M; Deas E; Houlden H; Mehta A; Hughes D; Cox TM; Deegan P; Schapira AH; Lees AJ; Limousin P; Jarman PR; Bhatia KP; Wood NW; Hardy J; Foltynie T
    Mov Disord; 2013 Feb; 28(2):232-236. PubMed ID: 23225227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
    Parlar SC; Grenn FP; Kim JJ; Baluwendraat C; Gan-Or Z
    Mov Disord; 2023 Mar; 38(3):489-495. PubMed ID: 36598340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.